

EFS

Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007

Reply filed August 20, 2010

Page 19 of 21

### REMARKS

Claims 1, 7-8 and 94-110 are pending in the subject application. By this amendment, Claims 1, 8 and 99-102 have been amended. Applicant maintains that the amendments to the claims do not raise an issue of new matter. Support for the amendments can be found at least in the previous version of the claims.

The specification has been amended to correct the priority data for the subject application, to clarify the Statement of Government Support, to insert Sequence Listing identifiers, and to designate trademarks. Applicant maintains that the amendments to the specification do not raise an issue of new matter.

Entry of the amendments is respectfully requested.

### Rejections under 35 U.S.C. §112, Second Paragraph

Claims 1, 7-8 and 94-110 are rejected because the Examiner indicated that it is unclear if in the recited structures, the HN- from the variable A is from the HN- of the amino acid alanine or is an additional HN- component that would lead to a hydrazine bond to the HN- of the amino acid. In reply, the applicant notes that the nitrogen is explicitly written to emphasize the nature of the linkage between the Ala and the various moieties attached to it. There is not an additional HN- that would lead to a hydrazine bond to the HN- of the amino acid. Applicant respectfully maintains that this convention is clear to one skilled in the art. As evidence of the use of this convention in the art, applicant refers the Examiner to the attached publication in the Journal of the American Chemical Society (Lee JH et al., A highly potent and selective PKC $\alpha$  inhibitor generated via combinatorial modification of a peptide scaffold. J Am Chem Soc. 2004 Mar 24;126(11):3394-5. Epub March 2, 2004). Accordingly, reconsideration and withdrawal of this rejection are respectfully requested.

EFS

Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007

Reply filed August 20, 2010

Page 20 of 21

Claims 1, 7 and 94-98 are rejected due to the recitation in Claim 1 of "amino acid mimetic" and "analogous amino acid mimetic." The claims have herein above been amended to no longer recite these terms, thereby obviating this rejection.

Dependent Claim 8 is rejected as lacking antecedent basis in Claim 1, from which it depended. Claim 8 has herein above been rewritten as an independent claim, thereby obviating this rejection.

Dependent Claims 99-100 and 101-102 are rejected as lacking antecedent basis in Claim 1, from which they depended. The claims have herein above been amended so that Claims 99-102 now depend from independent Claim 8, thereby obviating this rejection.

#### Rejections under 35 U.S.C. §112, First Paragraph

Claims 1, 7 and 94-98 are rejected due to the recitation in Claim 1 of "amino acid mimetic" and "analogous amino acid mimetic." The claims have herein above been amended to no longer recite these terms, thereby obviating this rejection.

#### Supplemental Information Disclosure Statement

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the references that are listed on the attached form PTO/SB/08A.

EFS

Applicant: David S. Lawrence

Appl'n. No.: 10/589,029

Filed: June 21, 2007

Reply filed August 20, 2010

Page 21 of 21

### CONCLUSIONS

In view of the amendments and remarks made hereinabove, reconsideration and withdrawal of the objections and rejections in the May 28, 2010 Office Action and passage of the pending claims to allowance are respectfully requested. If there is any minor matter preventing the allowance of the subject application, the Examiner is requested to telephone the undersigned attorney.

The Patent Office is authorized to charge the \$180.00 fee for submitting an Information Disclosure Statement to Deposit Account No. 01-1785. No other fee is deemed necessary in connection with the filing of this Amendment and Information Disclosure Statement. However, if any other fee is required to preserve the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785. Overpayments may also be credited to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: August 20, 2010  
New York, New York

By /Alan D. Miller/  
Alan D. Miller, Reg. No. 42,889